Innovations
Commented by Armin Schulz on October 3rd, 2025 | 07:05 CEST
BioNxt Solutions' pharmaceutical revolution: New ways of administering blockbuster drugs
Imagine chemotherapy without severe side effects or a blockbuster drug without needles. What sounds like a pipe dream is now becoming reality thanks to innovative drug delivery systems. They are revolutionizing billion-dollar markets from oncology to obesity therapy and laying the foundation for exponential growth. For investors, this technological breakthrough opens up a unique investment window. BioNxt Solutions is at the forefront of this movement.
Read
Commented by Nico Popp on September 26th, 2025 | 07:30 CEST
AI is conquering increasingly more areas: SAP and Amazon are targeting small and mid-sized businesses, while NetraMark is winning over the biotech industry
Will AI become our new god? This question is currently being explored in depth by the German philosopher Markus Gabriel in a well-known German podcast. And although the question may cause unease for many, Gabriel's conclusions are ultimately anything but pessimistic. SAP and Amazon are also looking to the future with optimism: Together with OpenAI, they are now building an AI infrastructure in Germany. The goal: to enable public authorities and companies to use the latest AI tools in a legally compliant manner, without European data leaving the continent. The initiative demonstrates that AI will conquer many more areas in the coming years. One of these areas is medical research. The innovative company NetraMark is using its AI solution to deliver faster results and lower costs for future-focused projects, such as the fight against cancer.
Read
Commented by Armin Schulz on September 22nd, 2025 | 07:40 CEST
BioNxt Solutions: Your chance to get in early on the next biotech blockbuster
Imagine a cancer treatment that doesn't affect the whole body, but instead acts only at the tumor site. Or a treatment for multiple sclerosis that no longer needs to be swallowed, but simply dissolves under the tongue. What sounds like a dream of the future is already being pursued with full force by the German-Canadian biotech company BioNxt Solutions. The Company is developing two innovative platform technologies that aim to solve some of the biggest challenges in modern medicine. For investors, this opens up extraordinary opportunities.
Read
Commented by Nico Popp on September 18th, 2025 | 07:05 CEST
Understanding metabolism, generating returns: Vidac Pharma, Roche, AstraZeneca
In the search for new treatments against diseases, researchers agree on one thing: the holy grail is unlikely to be found. Instead, it is incremental improvements and combination therapies that promise progress in complex diseases such as cancer. Cell metabolism is considered a promising approach, for example, in cancer, when the metabolism of a cancer cell is disrupted, the cell dies. In this article, we present current approaches and also discuss a biotechnology company that is wholly dedicated to cellular metabolism.
Read
Commented by Fabian Lorenz on September 16th, 2025 | 07:00 CEST
Hot Stock shakes up Big Pharma! BioNxt Solutions aims to replace Ozempic weight loss injection!
BioNxt is currently shaking up Big Pharma. The announcement that it plans to replace the Ozempic weight loss injection with an oral dissolvable film is once again fueling speculation about the share price. Just like in the multiple sclerosis space, the Company aims to disrupt a billion-dollar obesity market. Further exciting operational news is expected in the coming months. Key patents are already in place. With a market capitalization of around CAD 100 million, the Canadian-German life sciences company is far from expensive – even for Big Pharma. The major corporations will undoubtedly be watching BioNxt's development very closely in the coming months. Until then, the stock is likely to trade significantly higher.
Read
Commented by Nico Popp on September 15th, 2025 | 07:15 CEST
No more diet injections! Innovations in weight loss drugs: BioNxt Solutions, Merck & Co., Novo Nordisk
As recently reported by the United Nations Children's Fund (UNICEF), for the first time, more children worldwide are obese than underweight. While this is a great success in the fight against hunger, it also poses new risks. Severe overweight in childhood leads to obesity and associated diseases in adulthood, such as cardiovascular problems and diabetes. The treatment of overweight and diabetes in children is therefore likely to play an even more significant role in the future. GLP-1 receptor agonists have been popular for several years now in the form of modern weight loss injections. With patents expiring soon, experts anticipate substantial further growth and development in this rapidly expanding market. We explain who could benefit and what the future holds for modern diet medications.
Read
Commented by Fabian Lorenz on September 9th, 2025 | 07:20 CEST
Takeover candidate! Novo Nordisk and Eli Lilly eyeing BioNxt Solutions
A portfolio rocket for the coming weeks? The shares of BioNxt Solutions are certainly worth a closer look. There was no sign of a summer slump at this company - quite the opposite, as one major announcement followed another, and the newsflow continues into September. The Canadian-German life sciences company specializes in innovative drug delivery technologies. The latest bombshell: BioNxt aims to replace the Ozempic weight-loss injection with a tablet-like oral form of administration. This move opens the door to another billion-dollar market and positions the Company as a takeover candidate. Novo Nordisk, Eli Lilly, and others are engaged in fierce competition and are hungry for innovations – like those developed by BioNxt. The stock remains attractively priced.
Read
Commented by André Will-Laudien on July 15th, 2025 | 07:30 CEST
Bitcoin and exchanges in IPO and hysteria mode! AI millions from NetraMark Holdings, Clara Technologies, BitMine, and D-Wave
The recent IPOs on the NASDAQ show just how quickly innovations can materialize. No sooner are they listed than they skyrocket, because what is new must be good! Or is it? From a distance, stock market professionals are beginning to wonder whether everything is still above board. The crypto company BitMine, for example, gained 2,000% within two weeks, only to lose a third of its value after announcing a USD 2 billion capital increase. Clara Technologies debuted on the stock market in January with prices around CAD 0.50. By the end of last week, the share price had exploded to around CAD 16, a 32-fold increase. Our advice: Investors should examine business models very carefully before entering the ring. AI newcomer NetraMark is fully embracing the trends toward digitization and increased accuracy through the use of AI in the clinical trial sector. Where do the opportunities and risks lie for agile investors?
Read
Commented by André Will-Laudien on July 15th, 2025 | 07:20 CEST
Infrastructure hype in 2025: Sustainable construction is in demand! Keep an eye on Siemens, Heidelberg Materials, Argo Graphene, and Porr
A lot is falling apart around the world right now, not just in material terms, but also structurally. Wars, geopolitical tensions, and economic upheavals are putting entire regions under pressure. Although Germany is not directly affected militarily, the consequences of the wear and tear are clearly noticeable here as well: our infrastructure, which has been criminally neglected for decades, is increasingly showing cracks, both literally and figuratively. Dilapidated bridges, overloaded rail networks, outdated power lines, and sluggish fibre optic expansion are now even hampering competitiveness. Europe has recognized these weaknesses and is responding with ambitious investment programs. The Green Deal, the EU Recovery Fund, and national economic stimulus packages are set to pour billions into sustainable mobility, energy supply, digitalization, and resilience. Where are the winners for your portfolio?
Read
Commented by Armin Schulz on July 9th, 2025 | 07:05 CEST
Liver cancer breakthrough fuels billion-dollar market: How Bayer, Vidac Pharma, and Novo Nordisk can now power your portfolio
The pharmaceutical industry is undergoing its biggest upheaval in decades. Megatrends such as cancer treatment, fueled by recent breakthroughs like the EMA approval of the liver cancer therapy Lenvima®/Keytruda®, and revolutionary therapies for diabetes and obesity are generating billion-dollar markets. Those who understand these growth drivers will identify lucrative opportunities. Innovative active ingredients are not only changing medicine but also unlocking exceptional return potential for forward-thinking investors. This dynamic draws attention directly to the strategies of Bayer, Vidac Pharma, and Novo Nordisk.
Read